Circulating IL-35 in pancreatic ductal adenocarcinoma patients
Circulating IL-35 in pancreatic ductal adenocarcinoma patients
复制标题
胰腺导管腺癌患者的循环 IL-35。
DOI：
10.1016/j.humimm.2013.09.018
复制
发表时间：
2014-01-01
期刊：
影响因子：
2.7
通讯作者：
Hao, Jihui
中科院分区：
文献类型：
--
作者：
Jin, Peng;Ren, He;Hao, Jihui
IL-35是一种新型的抑制性细胞因子，主要由调节性T细胞（Tlc）产生，并且是Treg介导的免疫抑制所必需的。然而，胰腺导管腺癌（PDAC）患者的血浆IL-35水平从未被研究过。在这项研究中，我们发现PDAC患者的血浆IL-35水平比正常对照组更显著升高（134.53 +/- 92.45 pg/mL vs. 14.26 +/- 6.56 pg/mL）。IL-35 mRNA水平与血浆IL-35水平呈正相关（EBI 3，R = 0.925，p < 0.01; p35，R = 0.916，p < 0.01）。此外，IL-35表达水平与淋巴结转移（p = 0.001）和晚期肿瘤分期（p = 0.002）相关。对于手术切除的患者，高IL-35表达水平与肿瘤大小（p < 0.01）、较高TNM分类T分期（p < 0.05）和晚期肿瘤分期（p < 0.05）相关。结论：PDAC患者外周血IL-35水平显著升高，提示调控IL-35的表达可能为PDAC患者尤其是可切除PDAC患者的治疗提供新的可能靶点。(C)2013年美国组织相容性和免疫遗传学学会。爱思唯尔公司出版。All rights reserved.
IL-35 is a novel inhibitory cytokine that is mainly produced by regulatory T-cells (Tregs) and is required for Treg-mediated immunosuppression. However, the plasma levels of IL-35 in patients with pancreatic ductal adenocarcinoma (PDAC) have never been investigated. In this study, we found that plasma IL-35 levels more significantly increased in PDAC patients than in normal controls (134.53 +/- 92.45 pg/mL vs. 14.26 +/- 6.56 pg/mL). IL-35 mRNA levels were positively correlated with plasma IL-35 levels (EBI3, R = 0.925, p < 0.01; p35, R = 0.916, p < 0.01). Furthermore, IL-35 expression levels were associated with lymph node metastasis (p = 0.001) and late tumor stage (p = 0.002). For the resected patients, high IL-35 expression levels were associated with large tumor size (p < 0.01), higher TNM classification T staging (p < 0.05), and late tumor stage (p < 0.05). In conclusion, circulating IL-35 in PDAC patients significantly increased, suggesting that regulating the expression of IL-35 may provide a new possible target for the treatment of PDAC patients, especially for the resectable ones. (C) 2013 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.